1 Department of Orthopaedic Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA. 2 Department of Dermatology, University of California, San Francisco, CA, USA. 3 Department of Pathology, Cedars ...

Because liposarcoma is rare, commonly recurs, and has evolving treatments, it cannot be overemphasized that patients should be referred to specialized cancer treatment centers where a larger ...

Yondelis is also indicated for the treatment of patients with metastatic liposarcoma. Yondelis is indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma ...

“Additionally, as we have contributed to the development of trabectedin over the years, we were excited to see its approval in early 2024 as a monotherapy in the second-line treatment for two of the ...

Trabectedin is under clinical development by Pharma Mar and currently in Phase II for Dedifferentiated Liposarcoma. According to GlobalData, Phase II drugs for Dedifferentiated Liposarcoma does not ...

classical lipoma, although adipocytes are not multivacuolated cells; lipoblastoma, normally composed of immature cells that resemble fetal adipose tissue in different development stages; and ...